Who are Menadion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Menaquinone, SODIUM ASCORBATE, Infuvite Adult, Hectorol, Zemplar, Fosamax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/menadione.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Menadion — Competitive Intelligence Brief

Menadion (MENADIONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D [EPC]. Area: Other.

marketed Vitamin D [EPC] Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A Other Small molecule Live · refreshed every 30 min

Target snapshot

Menadion (MENADIONE) — Eli Lilly.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Menadion TARGET	MENADIONE	Eli Lilly	marketed	Vitamin D [EPC]	Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A	1982-01-01
Menaquinone	Menaquinone	Cairo University	marketed		Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A
SODIUM ASCORBATE	SODIUM ASCORBATE		marketed	Vitamin D [EPC]		2006-01-01
Infuvite Adult	Colecalciferol	Novartis	marketed	Vitamin D	Vitamin D3 receptor	2000-01-01
Hectorol	DOXERCALCIFEROL	Sanofi	marketed	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1999-01-01
Zemplar	PARICALCITOL	AbbVie	marketed	Vitamin D2 Analog [EPC]	Vitamin D3 receptor	1998-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	marketed	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-12-05 — Fosamax · 9592195 · US

Sponsor landscape (Vitamin D [EPC] class)

· 2 drugs in this class
Abramson Cancer Center at Penn Medicine · 1 drug in this class
Eli Lilly · 1 drug in this class
Heather Wakelee · 1 drug in this class
Merck And Co Inc · 1 drug in this class
Mohammed Milhem, MBBS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Menadion — Competitive Intelligence Brief. https://druglandscape.com/ci/menadione. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab